CN102223812A - 婴儿脂肪量的调节 - Google Patents
婴儿脂肪量的调节 Download PDFInfo
- Publication number
- CN102223812A CN102223812A CN2009801466665A CN200980146666A CN102223812A CN 102223812 A CN102223812 A CN 102223812A CN 2009801466665 A CN2009801466665 A CN 2009801466665A CN 200980146666 A CN200980146666 A CN 200980146666A CN 102223812 A CN102223812 A CN 102223812A
- Authority
- CN
- China
- Prior art keywords
- composition
- purposes
- baby
- albumen
- aforementioned
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 230000035935 pregnancy Effects 0.000 claims abstract description 5
- 235000013350 formula milk Nutrition 0.000 claims description 35
- 230000009984 peri-natal effect Effects 0.000 claims description 6
- 210000000577 adipose tissue Anatomy 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 102000015781 Dietary Proteins Human genes 0.000 claims 2
- 108010010256 Dietary Proteins Proteins 0.000 claims 2
- 235000021245 dietary protein Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 26
- 108090000623 proteins and genes Proteins 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 12
- 235000016709 nutrition Nutrition 0.000 abstract description 8
- 206010033307 Overweight Diseases 0.000 abstract description 6
- 208000008589 Obesity Diseases 0.000 abstract description 3
- 235000020824 obesity Nutrition 0.000 abstract description 3
- 238000009825 accumulation Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000004584 weight gain Effects 0.000 abstract description 2
- 235000019786 weight gain Nutrition 0.000 abstract description 2
- 239000003925 fat Substances 0.000 description 27
- 235000019197 fats Nutrition 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 24
- 108010046377 Whey Proteins Proteins 0.000 description 16
- 102000007544 Whey Proteins Human genes 0.000 description 16
- 239000005862 Whey Substances 0.000 description 14
- 235000009508 confectionery Nutrition 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 235000020256 human milk Nutrition 0.000 description 8
- 210000004251 human milk Anatomy 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 235000020247 cow milk Nutrition 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000186012 Bifidobacterium breve Species 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 108010028463 kappa-casein glycomacropeptide Proteins 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
降低处于危险的新生人类婴儿脂肪量蓄积的方法，该方法包括在至少部分新生儿阶段给婴儿施用治疗量的营养组合物，其包含蛋白的量使所述组合物每100千卡包含大于2.4g的蛋白。因为在出生第一周重量增量与成年的超重相关，这可能提供了降低婴儿在其后生活中发展为肥胖的危险的方法。还要求保护在怀孕期给母亲施用DHA。
Description
本发明涉及婴儿脂肪量的调节。
对于所有婴儿都建议进行母乳喂养。但是在一些情况下，出于医学原因使母乳喂养不足、失败或不可取，或者母亲选择不进行母乳喂养。针对这些情况开发了婴儿配方。对人乳成分更充分的了解为研制成分更加接近于人乳的婴儿配方提供了机会。在研制配方时，特别考虑设计配方，使得摄入后生长和代谢模式能够与母乳喂养的婴儿相似，以期能够保证其在随后的童年和成年期产生相似的健康发育特征。
传统婴儿配方分为两类：从出生到4至6个月的婴儿的初生婴儿配方，其为该年龄组提供了完全营养，以及喂养四至六个月至十二个月之间的婴儿的所谓跟进配方。随着断奶的过程结合使用越来越多的其他食物，例如婴儿营养米粉和水果泥、蔬菜，及其他食物。
膳食蛋白提供了蛋白质合成与成长所需的必需氨基酸，在婴儿配方中，蛋白质量和蛋白数量两者都是重要的。婴儿配方通常是基于牛乳，但牛乳的氨基酸谱与人乳显著不同。过去，为了提供足够的必需氨基酸，基于牛乳的婴儿配方不得不具有比人乳显著地更高的蛋白含量，事实上，成熟人乳每100千卡1.4至1.8g范围的蛋白，与任何哺乳动物中所见的蛋白浓度相比是最低的。在过去的5至10年里，这一发现引导了降低婴儿配方中蛋白含量的倾向。例如，在EP1220620中，提出以重量计蛋白量为9.0％至10.0％重量的婴儿配方组成。这相当于1.8g蛋白/100千卡，与成熟人乳中的蛋白水平相当。
一般地，婴儿配方的蛋白含量中：初生婴儿配方在1.8至3.5g/100千卡，为该范围的较低端；跟进配方的蛋白含量倾向于该范围的较高端。例如，雀巢
初生婴儿配方的蛋白含量是1.83g/100千卡，雀巢 
跟进婴儿配方的蛋白含量是3.1g/100千卡。
在婴儿初生后的头几个月喂养约1.8g蛋白/100千卡初生婴儿配方已显示出某些益处。例如，根据WO2006/069918，喂以包含1.83g蛋白/100千卡的婴儿配方的婴儿中血浆IGF-1水平的衍变与喂以含2.39g蛋白/100千卡的婴儿配方的相比，前者与出生几个月母乳喂养的婴儿更为接近。
在婴猴中已证实，降低配方的蛋白含量与用较高蛋白含量配方喂养组相比，在成长模式与生命早期胰岛素与葡萄糖代谢方面与母乳喂养对照组更相似。其含义是增加的IGF-1水平可导致不同的身体组成并且增加在后期生活中患肥胖症的倾向。儿童超重和肥胖常影响到世界范围1800万5岁以下的儿童。几乎30％的美国儿童和青少年及10％至30％的欧洲儿童是超重的或肥胖的。
因此，显然需要进一步研究早期营养对婴儿期身体组成及其在生命后期发展为肥胖的危险的影响。
发明概述
现已令人惊奇的发现，在新生儿阶段用相对较高蛋白含量的婴儿配方喂养可降低在新生儿阶段脂肪量蓄积(与在相同阶段用较低蛋白含量的婴儿配方的婴儿蓄积的脂肪量相比)。
因此，本发明提供了蛋白质原料在制备营养组合物中的用途，所述组合物用于给人类婴儿在至少部分新生儿阶段施用，使得婴儿在新生儿阶段中降低脂肪量的蓄积，其中组合物每100千卡含有至少2.4g的蛋白质。
本发明还延伸了蛋白质原料在制备营养组合物中的用途，所述组合物用于给至少部分新生儿阶段的人类婴儿施用，使得降低随后生活中发展为肥胖症的风险，其中每100千卡该组合物含有至少2.4g的蛋白质。
本发明还延伸至降低处于危险中的新生人类婴儿脂肪量蓄积的方法，该方法包括给至少部分新生儿阶段的婴儿施用治疗量的营养组合物，所述营养组合物包含蛋白的量使组合物每100千卡包含多于2.4g蛋白。
本发明还延伸至降低婴儿在其随后生活中发展为肥胖的可能性的方法，方法包括在至少部分新生儿阶段喂养营养组合物，所述营养组合物包含蛋白的量使组合物每100千卡包含多于2.4g蛋白。
在生命的头几周期间体重增量与其成年时超重有关(Stettler N，Stallings VA，Troxel AB，Zhao J，Schinnar R，Nelson SE，Ziegler EE，Strom BL.Weight gain in the first week of life and overweight in adulthood：a cohort study of European American subj ects fed infant formula.Circulation(2005).111：1897-903)。因此降低新生儿阶段中脂肪量蓄积的营养干预-或者换言之，降低导致新生儿阶段(模拟母乳喂养婴儿)脂肪量蓄积-可降低其随后生活中超重的危险。
发明详述
在本说明书中，以下表达具有以下含义：
“婴儿”是指12个月以下年龄的儿童。
“新生儿”是指出生第一个月的婴儿。
“新生儿阶段”是指出生的第一个月。
所有百分数与比值是指重量，除非另外说明。
以具体的每升千卡数提到的营养组合物的能量密度，是指在粉状产品的背景下，按照产品提供的说明复配后的产品。
优选地，本发明中使用的营养组合物包含2.4至3.0g蛋白/100千卡，更优选包含2.4至2.8g/100千卡。
优选地，至少在婴儿生命中的头两周喂养包含多于2.4g蛋白/100千卡的营养组合物。任选地用所述组合物喂养可持续整个新生儿阶段，之后婴儿可用包含1.7至2.0g蛋白/100千卡的营养组合物喂养。
只要符合必需氨基酸含量的最低需要并保证令人满意的生长，蛋白质的原料对本发明并非关键。因此可以使用基于牛乳蛋白质的蛋白质原料，例如乳清、酪蛋白及其混合物，和基于大豆的蛋白质原料。就乳清蛋白质而言，蛋白质原料可以基于酸乳清或甜乳清、乳清蛋白质分离物或其混合物，并且可以包含任意期望比例的α-乳球蛋白和β-乳球蛋白。
然而，优选的蛋白质原料是基于修饰的甜乳清。甜乳清是奶酪生产中容易获得的副产品，并且经常用在基于牛乳的婴儿配方的制备中。但是，甜乳清含有一种称为酪蛋白糖巨肽(caseino-glyco-macropeptide)(CGMP)的成分，该成分不理想地富含苏氨酸且匮乏色氨酸。从甜乳清中除去CGMP产生苏氨酸含量更接近于人乳的蛋白质。接着，这一修饰的甜乳清可以用含量低的那些氨基酸(主要为组氨酸、精氨酸和色氨酸)加以补充。从甜乳清中除去CGMP的方法描述于EP 880902中，并且基于这一修饰的甜乳清的婴儿配方在WO 01/11990中有描述。这样的蛋白原料已在动物和人体研究中显示具有蛋白质效率比、氮可消化性、生物学价值，并且净蛋白质利用率与每100千卡具有更高蛋白含量标准乳清制备的蛋白原料相当，并能使婴儿有满意的生长。如果使用修饰的甜乳清作为蛋白元，可补充用量为0.1％至3％重量的游离精氨酸和/或用量为0.1％至1.5％重量的游离组氨酸。
蛋白可以是完整的或是水解的或完整与水解蛋白的混合物，尽管完整蛋白通常是优选的。但是，例如对于据信处于发生牛乳过敏危险的婴儿而言可能需要提供部分水解的蛋白(水解度在2％至20％之间)。如果需要水解蛋白，蛋白源可以按需要并按照技术上已知的方法进行水解。例如，可通过如EP322589中公开的两步酶解乳清组分制备乳清蛋白水解物。如果用作起始原料的乳清组分基本上无乳糖，那么，则发现蛋白在水解过程中承受少得多的赖氨酸断裂。这使得赖氨酸断裂程度从赖氨酸总重量的约15％至少于赖氨酸重量的约10％；例如赖氨酸重量的约7％，这大大改善了蛋白源的营养质量。
优选地本发明中使用的营养组合物是婴儿配方。这样的全营养组合物同样将包含见于婴儿配方中常规类型的其他成分，例如碳水化合物类、脂肪类、维生素类和矿物质类以及半必需营养素。
碳水化合物的优选来源是乳糖，尽管其他碳水化合物例如蔗糖、麦芽糊精和淀粉也可以加入。优选地碳水化合物来源占配方总能量的35％至65％之间。
脂质来源可以是任何适于婴儿配方使用的脂质或脂肪。优选的脂肪来源包括棕榈油、高油酸葵花籽油和高油酸红花油。当少量的油可能含有大量预形成的花生四烯酸和二十二碳六烯酸时(例如鱼油或微生物油)，也可以加入必需脂肪酸亚油酸和α-亚麻酸。总之，脂肪含量优选占配方总能量的30％至55％。脂肪来源优选具有比例约为5∶1至15∶1的n-6至n-3脂肪酸；例如约8∶1至约10∶1。
婴儿配方同样将包含理解为日常膳食中基本的和营养上有意义量的全部维生素和矿物质。对某些维生素和矿物质已建立了最低要求。任选存在于婴儿配方的矿物质、维生素和其他营养素的实例包括维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素E、维生素K、维生素C、维生素D、叶酸、肌醇、烟酸、生物素、泛酸、胆碱、钙、磷、碘、铁、镁、铜、锌、镁、氯、钾、钠、硒、铬、钼、牛磺酸和L-肉碱。矿物质常以盐的形式加入。具体矿物质与其他维生素的存在与用量将取决于要使用的婴儿群体。
如果需要，婴儿配方可包含乳化剂和稳定剂，例如大豆卵磷脂、枸橼酸的单甘油酯和二甘油酯等。特别是在配方是以液体形式提供的情况下。
婴儿配方可任选包含可能具有有益作用的其他物质，例如纤维类、乳铁蛋白、核苷酸、核苷等。益生菌例如鼠李糖乳杆菌ATCC 53103、鼠李糖乳杆菌CGMCC 1.3724、罗伊乳杆菌ATCC 55730、罗伊乳杆菌DSM17938、乳双歧杆菌CNCM I-3446、长双歧杆菌ATCC BAA-999，Danisco销售的商品名为Bb-03的短双歧杆菌菌株、Morinaga销售的商品名为M-16V的短双歧杆菌菌株，Institut Rosell(Lallemand)销售的商品名为R0070的短双歧杆菌菌株，也包括Procter & Gamble Co.销售的商品名为Bifantis的婴儿双歧杆菌菌株。
婴儿配方可以任何适宜的方式制备。例如，婴儿配方可通过将适当比例的蛋白源、糖源和脂肪源搅拌在一起进行制备。如果使用乳化剂，可在此阶段将乳化剂包含在该混合物中。维生素与矿物质可在此时点加入，但通常稍后加入以避免热降解。可将任何脂溶性维生素、乳化剂等溶解在脂肪源中，之后混合。然后可将水，优选经过反渗析的水混合进去，以形成液体混合物。
然后将液体混合物进行热处理以减少细菌载量。例如，液体混合物可被迅速加热至约80℃至约110℃温度范围约5秒钟至约5分钟。这可通过注蒸汽或热交换器、例如平板加热器进行。
然后将液体混合物冷却至约60℃至约85℃；例如通过快速冷却。然后可在两个阶段对液体混合物匀化；例如，第一阶段在约7MPa至约40MPa，和第二阶段在约2MPa至约14MPa。然后将匀化的混合物进一步冷却并可加入任何热敏感成分例如维生素和矿物质。在这一时点方便地对匀化混合物的pH和固体含量进行标准化。
如果需要制备粉状婴儿配方，将匀化混合物转移至适宜的干燥设备例如喷雾干燥机或冷冻干燥机，并被转化成粉末。粉末应当具有重量低于约5％的水分。
如果需要制备液体婴儿配方，将匀化混合物填充至适宜的容器中；优选无菌填充。但是，液体婴儿配方也可被保留在容器中。用于进行这种性质填充的适宜设备是可商购得到的。液体婴儿配方可以是具有约10％至约14％重量的固体含量的易于喂养的配方，或者可以是浓缩物的形式；通常约20％至26％重量的固体含量。
在本发明的一个实施方案中，DHA(二十二碳六烯酸)被用作本发明组合物的一部分，特别是在围产期阶段。可包括给怀孕的母亲补充DHA，和/或给围产期的年轻婴儿(优选自出生至6月龄，自出生至3月龄，自出生至4周龄，或自出生至1周龄)施用DHA。已有证据(见实施例3)，这样施用DHA对出生后的婴儿脂肪量具有正面影响。在一个实施方案中，本发明包含以上描述的蛋白特征的用途与施用以及DHA的施用。在一个实施方案中，DHA(二十二碳六烯酸)被给予婴儿施用。在一个实施方案中，DHA(二十二碳六烯酸)被给予妊娠期的母亲施用，优选在妊娠期的最后6个月、最后3个月、最后4周、或最后一周施用。在一个实施方案中，DHA被给予妊娠期的母亲(优选按照以上方案)和出生后婴儿(优选按照以上方案)施用。
在一个实施方案中，DHA以0.1％至4％的水平被包含在膳食中，优选在0.3％至2.5％，最优选在0.5％至1％。在一个实施方案中，补充是在0.75％的DHASCO油(相当于2.4％DHA的总脂肪酸)中。
在一个实施方案中，本发明包括给围产期婴儿施用的根据以上所述的组合物，以便在新生儿期获得较低的身体脂肪量蓄积。
在一个实施方案中，本发明包括“套装”，其包含给以上描述的婴儿施用的组合物，还包含给怀孕女性施用的组合物，优选在妊娠期的最后6个月、最后3个月或最后4周，以使新生儿期的婴儿获得较低的身体脂肪量蓄积。
在一个实施方案中，将低的体重积累引用在与接受常规膳食的婴儿所获得的平均脂肪体重积累的比较中。
现在本发明将通过参照以下实施例进一步说明。
实施例1
以下给出本发明中使用的合适婴儿配方成分的实例：
| 营养 | 每100千卡 | 每升 |
| 能量(千卡) | 100 | 670 |
| 蛋白(g) | 2.70 | 18.1 |
| 脂肪(g) | 5.3 | 35.5 |
| 亚油酸(g) | 0.76 | 5.1 |
| α-亚麻酸(mg) | 95 | 635 |
| 乳糖(g) | 10.38 | 69.6 |
| 矿物质(g) | 0.45 | 3.0 |
| Na(mg) | 26 | 180 |
| K(mg) | 89 | 600 |
| Cl(mg) | 64 | 430 |
| Ca(mg) | 80 | 540 |
| P(mg) | 40 | 270 |
| Mg(mg) | 7 | 47 |
| Mn(μg) | 8 | 50 |
| Se(μg) | 2 | 14 |
| 维生素A(μg RE) | 105 | 540 |
| 维生素D(μg) | 1.5 | 10 |
| 维生素E(mg TE) | 0.8 | 5.4 |
| 维生素K1(μg) | 8 | 54 |
| 维生素C(mg) | 10 | 67 |
| 维生素B1(mg) | 0.07 | 0.47 |
| 维生素B2(mg) | 0.15 | 1.0 |
| 烟酸(mg) | 1 | 6.7 |
| 维生素B6(mg) | 0.075 | 0.50 |
| 叶酸(μg) | 9 | 60 |
| 泛酸(mg) | 0.45 | 3 |
| 维生素B12(μg) | 0.3 | 2 |
| 生物素(μg) | 2.2 | 15 |
| 胆碱(mg) | 10 | 67 |
| Fe(mg) | 1.2 | 8 |
| I(μg) | 15 | 100 |
| Cu(mg) | 0.06 | 0.4 |
| Zn(mg) | 0.75 | 5 |
给出下列实施例仅意在说明，而不应解释为对本申请主题的限制。
实施例2
在新生儿阶段膳食蛋白水平对婴儿身体组成的影响
本实例证实了对于一个月大的婴儿组，作为营养唯一来源所使用的婴儿配方的蛋白含量对其身体组成的影响。
随机、对照、双盲平行三组(喂养如下文详细描述的不同的婴儿配方的两个试验组，全部母乳喂养的婴儿的第三组作为参照)，在法国里昂的Réanimation Néonatale et Néonatologie，dela Croix Rousse医院按照1964年确立的赫尔辛基宣言(按修订版)的原则进行，并由CCPPRB Lyon A批准。
仅考虑入选在怀孕前有正常BMI的健康母亲的健康新生婴儿。符合这些标准、但母亲决定不母乳喂养处于头四个月大的婴儿，被随机分在两个试验组中的一个。已决定在其出生的头三个月仅母乳喂养的婴儿被分在参照组。
试验组中，一组喂以2.7g蛋白/100千卡(F2.7组)，另一组喂以1.83g蛋白/100千卡配方(F2.8组)。配方的详细组成在下表中给出。
两个配方是等热量的，具有670千卡/升的能量密度。在两种情况下，乳清酪蛋白比例为70∶30。提供以金属罐包装的配方，该金属罐标记有仅研究人员知道的字母条码。研究持续时间为12个月。
招募了238名婴儿(125名男孩和113名女孩)，74名在F1.8组，80名在F2.7组，84名在参照组。婴儿被喂以其所分配的配方，或随意地食用母乳作为营养的唯一来源。
在2周±2天龄时测定生长参数与身体组成。身体组成(BC)测定结果使用PEA-POD方法学以评价在其头一年期间的脂肪量(FM)增量。PEA-POD是设计使用与静水称重(水下称重)相似的原理测定从刚出生至6个月的婴儿BC。PEA-POD不使用水测定身体体积，而是使用排气量体积描记法作为密度测量技术，其中身体脂肪是从受试者直接测定质量体积以测定身体体积进行评价的。
配方组之间的热量摄入没有不同，并且在3组之间包括体重增量、头围和身长的生长参数也是相同的。如图1所示，在2周龄时，在2个配方喂养组之间蓄积脂肪量没有不同，但F1.8组与参比组相比显著更高(脂肪量：13.2±3.4vs 11.8±3.5％，p＜0.01；)。F2.7组与参比组相比脂肪量未显示出显著的差异(12.7±3.4％)(见图1)。
这些结果显示在出生头两周蛋白摄入不影响生长参数。但是，低蛋白摄入与母乳喂养相比导致肥胖增加。
实施例3
母方围产期DHA补充降低了新生豚鼠的脂肪量
在本发明的一个实施方案中，研究了DHA(二十二碳六烯酸)的影响。研究了母方二十二碳六烯酸(DHA)补充对新生豚鼠体重和脂肪量发展的影响。雌性豚鼠在怀孕与哺乳期间喂以0.75％DHASCO油(相当于2.4％的DHA的总脂肪酸；DHA是从Martek Biosciences，Columbia，MD，USA得到)补充膳食，或者不喂。在分娩后3天收集的豚鼠母乳的脂肪酸分析结果显示，仅在补充组中有可检测水平的DHA(总脂肪酸的1.8％)。在出生2天时，两组中新生豚鼠的体重是相同的(图2)，同时在DHA补充组中脂肪量的％显著更低(-DHA：16.0±0.6％；+DHA：12.7±0.4％，p＜0.001)(图4)。在第21天，组间脂肪量％的这一差异减弱了，但仍然显著(图3)。这些结果显示围产期DHA摄入降低了胎儿期间和/或出生后头几天的脂肪增量。理解DHA对出生早期及后续生活中脂肪组织发展的作用机制尚需进一步研究。
Claims (14)
1.用于制备在至少部分新生儿阶段给人婴儿施用使得降低新生儿阶段的脂肪量蓄积的营养组合物的蛋白来源的用途，其中所述组合物每100千卡包含至少2.4g的蛋白。
2.用于制备在至少部分新生儿阶段给人婴儿施用使得降低在后期生活中发展为肥胖的危险的营养组合物的蛋白来源的用途，其中所述组合物每100千卡包含至少2.4g的蛋白。
3.权利要求1或2的用途，其中所述组合物每100千卡包含2.4至3.0g蛋白。
4.前述任意权利要求的用途，其中所述组合物每100千卡包含2.4至2.8g蛋白。
5.前述任意权利要求的用途，其中所述营养组合物在整个新生儿阶段给婴儿施用。
6.前述任意权利要求的用途，其中所述蛋白是完整的。
7.权利要求1至5的任意项的用途，其中所述蛋白是部分水解的。
8.权利要求7的用途，其中所述蛋白的水解度在2％至20％之间。
9.前述任意权利要求的用途，其中所述营养组合物是婴儿配方。
10.前述任意权利要求的用途，其中先施用每100千卡具有至少2.4g蛋白含量的营养组合物，随后在婴儿头4个月的剩余时间里施用每100千卡具有1.7g至2.0g蛋白的蛋白含量的营养组合物。
11.前述任意权利要求的用途，其中DHA(二十二碳六烯酸)作为所述组合物的一部分给婴儿施用。
12.前述任意权利要求的用途，其中DHA(二十二碳六烯酸)在妊娠期间给母亲施用，优选在妊娠期的最后3个月。
13.根据前述任意权利要求的给予围产期婴儿施用的组合物，以获得在新生儿阶段低的身体脂肪量蓄积。
14.包含权利要求13或前述权利要求的任意项的组合物的套装，所述套装还包含用于给怀孕女性施用的组合物，优选在其妊娠期的最后3个月，使得在新生儿阶段的婴儿获得低的身体脂肪量蓄积。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08170936.2 | 2008-12-08 | ||
| EP08170936 | 2008-12-08 | ||
| PCT/EP2009/065662 WO2010066569A1 (en) | 2008-12-08 | 2009-11-23 | Modulation of infant fat mass |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102223812A true CN102223812A (zh) | 2011-10-19 |
Family
ID=40688400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801466665A Pending CN102223812A (zh) | 2008-12-08 | 2009-11-23 | 婴儿脂肪量的调节 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9462821B2 (zh) |
| EP (1) | EP2373183A1 (zh) |
| CN (1) | CN102223812A (zh) |
| AU (1) | AU2009326395B2 (zh) |
| BR (1) | BRPI0922247A2 (zh) |
| CA (1) | CA2745246A1 (zh) |
| MX (1) | MX2011004921A (zh) |
| RU (1) | RU2540541C2 (zh) |
| TW (1) | TW201026232A (zh) |
| WO (1) | WO2010066569A1 (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104135872A (zh) * | 2012-01-13 | 2014-11-05 | 雅培制药有限公司 | 妊娠期间特定碳水化合物系统用于影响后代的用途 |
| CN104839718A (zh) * | 2015-05-26 | 2015-08-19 | 南阳市汇博生物技术有限公司 | 一种粉剂型全营养配方食品及其生产工艺 |
| CN105813481A (zh) * | 2013-12-12 | 2016-07-27 | 雀巢产品技术援助有限公司 | 适用于婴儿的按年龄定制的营养体系 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2452574A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Age-tailored nutritional formula with particularly adapted caloric density for young infants |
| EP2452572A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Age-tailored nutritional formula with particularly adapted caloric density for infants and children |
| EP2452573A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Age-tailored nutritional composition with animal fats and vegetable fats |
| EP3366143A1 (en) | 2011-06-20 | 2018-08-29 | H.J. Heinz Company Brands LLC | Probiotic compositions and methods |
| EP2614724A1 (en) * | 2012-01-13 | 2013-07-17 | Abbott Laboratories | Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring |
| EP2614725A1 (en) * | 2012-01-13 | 2013-07-17 | Abbott Laboratories | Use of specific carbohydrate systems during pregnancy for improving lean body mass development and formation and reducing adverse health effects later in life in offspring |
| DK2994150T3 (da) | 2013-05-10 | 2019-06-11 | Heinz Co Brands H J Llc | Probiotika og fremgangsmåde til anvendelse |
| ES2780690T3 (es) | 2013-11-29 | 2020-08-26 | Société des Produits Nestlé SA | Composiciones nutricionales adaptadas a la edad con un contenido variable de proteínas |
| WO2015178761A1 (en) | 2014-05-19 | 2015-11-26 | N.V. Nutricia | Formulas comprising optimised amino acid profiles |
| US20160155347A1 (en) * | 2014-11-27 | 2016-06-02 | Nestec S.A. | Devices, systems and methods of assessing the foundations for the healthy development of an infant or a young child |
| ES2862774T3 (es) | 2016-04-11 | 2021-10-07 | Nestle Sa | Nutrición infantil que proporciona beneficios metabólicos |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007135141A1 (en) * | 2006-05-23 | 2007-11-29 | Nestec S.A. | Maternal supplement |
| CN101212911A (zh) * | 2005-07-01 | 2008-07-02 | 努特里希亚公司 | 含水解的蛋白质的婴儿营养品 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162472A (en) * | 1998-07-28 | 2000-12-19 | University Of Virginia Patent Foundation | Nutritional formula for premature infants and method of making |
| US7704542B2 (en) * | 2001-09-12 | 2010-04-27 | Xanodyne Pharmaceuticals, Inc. | Vitamin/mineral compositions with DHA |
| WO2005063050A1 (en) * | 2003-12-19 | 2005-07-14 | Abbott Laboratories | Method of increasing lean body mass and reducing body fat mass in infants |
| US20100022451A1 (en) | 2004-12-27 | 2010-01-28 | Nestec S.A. | Use of infant formula with reduced protein content |
| EP1962617A2 (en) * | 2005-12-23 | 2008-09-03 | N.V. Nutricia | Infant nutritional compositions for preventing obesity |
| EP1932437A1 (en) * | 2006-12-15 | 2008-06-18 | Nestec S.A. | Infant formula |
-
2009
- 2009-11-23 CN CN2009801466665A patent/CN102223812A/zh active Pending
- 2009-11-23 CA CA2745246A patent/CA2745246A1/en not_active Abandoned
- 2009-11-23 MX MX2011004921A patent/MX2011004921A/es unknown
- 2009-11-23 RU RU2011128029/13A patent/RU2540541C2/ru active
- 2009-11-23 US US13/133,295 patent/US9462821B2/en active Active
- 2009-11-23 WO PCT/EP2009/065662 patent/WO2010066569A1/en active Application Filing
- 2009-11-23 EP EP09756317A patent/EP2373183A1/en not_active Withdrawn
- 2009-11-23 AU AU2009326395A patent/AU2009326395B2/en active Active
- 2009-11-23 BR BRPI0922247-2A patent/BRPI0922247A2/pt not_active Application Discontinuation
- 2009-12-08 TW TW098141962A patent/TW201026232A/zh unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101212911A (zh) * | 2005-07-01 | 2008-07-02 | 努特里希亚公司 | 含水解的蛋白质的婴儿营养品 |
| WO2007135141A1 (en) * | 2006-05-23 | 2007-11-29 | Nestec S.A. | Maternal supplement |
Non-Patent Citations (2)
| Title |
|---|
| P. ROGGERO ET AL: "Influence of Protein and Energy Intakes on Body Composition of Formula-fed Preterm Infants After Term", 《JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION》 * |
| 无: "食品安全国家标准 婴儿配方食品", 《中华人民共和国国家标准》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104135872A (zh) * | 2012-01-13 | 2014-11-05 | 雅培制药有限公司 | 妊娠期间特定碳水化合物系统用于影响后代的用途 |
| CN105813481A (zh) * | 2013-12-12 | 2016-07-27 | 雀巢产品技术援助有限公司 | 适用于婴儿的按年龄定制的营养体系 |
| CN104839718A (zh) * | 2015-05-26 | 2015-08-19 | 南阳市汇博生物技术有限公司 | 一种粉剂型全营养配方食品及其生产工艺 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2745246A1 (en) | 2010-06-17 |
| BRPI0922247A2 (pt) | 2015-08-11 |
| US9462821B2 (en) | 2016-10-11 |
| AU2009326395B2 (en) | 2015-02-05 |
| RU2540541C2 (ru) | 2015-02-10 |
| TW201026232A (en) | 2010-07-16 |
| MX2011004921A (es) | 2011-05-30 |
| AU2009326395A1 (en) | 2010-06-17 |
| RU2011128029A (ru) | 2013-01-20 |
| WO2010066569A1 (en) | 2010-06-17 |
| US20110244072A1 (en) | 2011-10-06 |
| EP2373183A1 (en) | 2011-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102223812A (zh) | 婴儿脂肪量的调节 | |
| CA2532472C (en) | Infant or follow-on formula | |
| US9943097B2 (en) | Nutritional composition | |
| AU2007253309B2 (en) | Maternal supplement | |
| AU2006298720A1 (en) | Nutritional formulation for promoting catch-up growth | |
| ZA200600601B (en) | Infant or follow-on formula | |
| US20140044830A1 (en) | Infant formula for use in the prevention of cardiovascular diseases | |
| AU2014356449B2 (en) | Age-tailored nutritional compositions with a varying protein content | |
| TW201039759A (en) | Reduction of risk of obesity | |
| US20150272191A1 (en) | Formulas comprising optimised amino acid profiles | |
| WO2016050754A1 (en) | Nutritional composition with low content of medium-chain fatty acids in specific proportions, and its uses. | |
| AU2004248912B2 (en) | Infant or follow-on formula | |
| NZ708274B2 (en) | Formulas comprising optimised amino acid profiles | |
| MXPA06000005A (en) | Infant or follow-on formula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111019 |